

Raptor Pharmaceutical Corp
 Form 3
 October 03, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | |
|---|---------|--------------------------------------|---|--|
| 1. Name and Address of Reporting Person * | | 2. Date of Event Requiring Statement | 3. Issuer Name and Ticker or Trading Symbol | |
| Â Hyperion Trading Segregated Portfolio | | (Month/Day/Year) | Raptor Pharmaceutical Corp [RPTP] | |
| (Last) | (First) | 11/20/2012 | | |
| | | | 4. Relationship of Reporting Person(s) to Issuer | 5. If Amendment, Date Original Filed(Month/Day/Year) |
| C/O TMF LTD. GRAND PAVILLION COMM. CTR,Â 2ND FL., 802 WEST BAY ROAD, PO BOX 10338 | | | (Check all applicable) | |
| (Street) | | | <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner | |
| | | | <input type="checkbox"/> Officer <input type="checkbox"/> Other | |
| | | | (give title below) (specify below) | 6. Individual or Joint/Group Filing(Check Applicable Line) |
| | | | | <input checked="" type="checkbox"/> Form filed by One Reporting Person |
| | | | | <input type="checkbox"/> Form filed by More than One Reporting Person |

GRAND
 CAYMAN,Â E9Â KY1-1003
 (City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---|--|
| Common Stock, par value \$0.001 per share ⁽¹⁾ | 5,176,500 | D | Â |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date | 3. Title and Amount of Securities Underlying | 4. Conversion | 5. Ownership | 6. Nature of Indirect Beneficial Ownership |
|---|---|--|---------------|--------------|--|
|---|---|--|---------------|--------------|--|

Edgar Filing: Raptor Pharmaceutical Corp - Form 3

| | (Month/Day/Year) | | Derivative Security (Instr. 4) | | or Exercise Price of Derivative Security | Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | (Instr. 5) |
|------------------------------|---------------------|--------------------|-----------------------------------|----------------------------------|---|--|------------|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 1,000 | \$ 5.29 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 1,000 | \$ 5.27 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 1,000 | \$ 5.29 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 1,000 | \$ 5.27 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,000 | \$ 5.28 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 1,345 | \$ 5.25 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,000 | \$ 5.25 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 10,000 | \$ 5.24 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 10,000 | \$ 5.29 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 4,000 | \$ 5.31 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 4,000 | \$ 5.31 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 4,000 | \$ 5.31 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 4,000 | \$ 5.31 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 10,000 | \$ 5.29 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 22,500 | \$ 5.3 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 4,000 | \$ 5.26 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 4,000 | \$ 5.26 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.23 (2) | D | Â |

Edgar Filing: Raptor Pharmaceutical Corp - Form 3

| | | | | | | | |
|------------------------------|-------|-------|--------------|--------|-------------|---|---|
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.24 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.25 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.24 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.25 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.24 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.23 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.2 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,245 | \$ 5.2 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 10,000 | \$ 5.2 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 10,000 | \$ 5.2 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 120 | \$ 5.19 (2) | D | Â |
| Contracts for Difference (2) | Â (2) | Â (2) | Common Stock | 2,200 | \$ 5.19 (2) | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Hyperion Trading Segregated Portfolio C/O TMF LTD. GRAND PAVILLION COMM. CTR 2ND FL., 802 WEST BAY ROAD, PO BOX 10338 GRAND CAYMAN, E9 KY1-1003 | Â | Â X | Â | Â |

Signatures

/s/ David P.M. Blair and Richard A. Reinert 08/19/2014

Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Edgar Filing: Raptor Pharmaceutical Corp - Form 3

The shares of common stock, \$0.001 par value per share (the "Common Shares"), of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), reported herein were held by Hyperion Trading Segregated Portfolio (the "Reporting Person"), a segregated portfolio of Strategic Investment Tribes Fund SPC, a Cayman Islands exempted company registered as a segregated portfolio company, managed by Star Arrow Funds Expertise Ltd, a company organized under the laws of Anguilla ("Star").

- (2) On November 20, 2012, the Reporting Person held Contracts for Difference of the Common Shares (the "CFDs") reported herein with a securities broker (the "Issuer of the CFDs"), upon which, pursuant to an agreement between the Reporting Person and the Issuer of the CFDs, upon conversion of the CFDs (i) the Issuer of the CFDs would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion or, (ii) in the case that the purchase price of the CFDs (represented in column 4 of Table II) is less than the market price of the Common Shares at the time of conversion, the Reporting Person would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion. As of November 20, 2012, the Reporting Person and the Issuer of the CFDs had not converted any of the CFDs.

Â

Remarks:

1.Â Â TheÂ CommonÂ SharesÂ andÂ CFDsÂ reportedÂ hereinÂ representÂ securitiesÂ (theÂ "Securities")Â heldÂ byÂ th

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.